| pubmed-article:20189382 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20189382 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:20189382 | lifeskim:mentions | umls-concept:C0034251 | lld:lifeskim |
| pubmed-article:20189382 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:20189382 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:20189382 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:20189382 | pubmed:dateCreated | 2010-3-22 | lld:pubmed |
| pubmed-article:20189382 | pubmed:abstractText | Several series of thieno[2-3-b]pyridine analogues were synthesized and screened for inhibitory activity against eukaryotic elongation factor-2 kinase (eEF2-K). Modifications around several regions of the lead molecules were made, with a ring fusion adjacent to the nitrogen on the thienopyridine core being critical for activity. The most active compound 34 shows an IC(50) of 170 nM against eEF2-K in vitro. | lld:pubmed |
| pubmed-article:20189382 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20189382 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20189382 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20189382 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20189382 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20189382 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20189382 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20189382 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20189382 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:20189382 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:20189382 | pubmed:author | pubmed-author:SuzukiKazuyuk... | lld:pubmed |
| pubmed-article:20189382 | pubmed:author | pubmed-author:LockmanJeffre... | lld:pubmed |
| pubmed-article:20189382 | pubmed:author | pubmed-author:ReederMatthew... | lld:pubmed |
| pubmed-article:20189382 | pubmed:author | pubmed-author:BaichwalVijay... | lld:pubmed |
| pubmed-article:20189382 | pubmed:author | pubmed-author:AustinHarryH | lld:pubmed |
| pubmed-article:20189382 | pubmed:author | pubmed-author:OstaninKirill... | lld:pubmed |
| pubmed-article:20189382 | pubmed:author | pubmed-author:Adam... | lld:pubmed |
| pubmed-article:20189382 | pubmed:author | pubmed-author:HoffRyanR | lld:pubmed |
| pubmed-article:20189382 | pubmed:author | pubmed-author:BhoiteLeenaL | lld:pubmed |
| pubmed-article:20189382 | pubmed:copyrightInfo | 2010 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20189382 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20189382 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:20189382 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:20189382 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20189382 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20189382 | pubmed:pagination | 2283-6 | lld:pubmed |
| pubmed-article:20189382 | pubmed:meshHeading | pubmed-meshheading:20189382... | lld:pubmed |
| pubmed-article:20189382 | pubmed:meshHeading | pubmed-meshheading:20189382... | lld:pubmed |
| pubmed-article:20189382 | pubmed:meshHeading | pubmed-meshheading:20189382... | lld:pubmed |
| pubmed-article:20189382 | pubmed:meshHeading | pubmed-meshheading:20189382... | lld:pubmed |
| pubmed-article:20189382 | pubmed:meshHeading | pubmed-meshheading:20189382... | lld:pubmed |
| pubmed-article:20189382 | pubmed:meshHeading | pubmed-meshheading:20189382... | lld:pubmed |
| pubmed-article:20189382 | pubmed:meshHeading | pubmed-meshheading:20189382... | lld:pubmed |
| pubmed-article:20189382 | pubmed:meshHeading | pubmed-meshheading:20189382... | lld:pubmed |
| pubmed-article:20189382 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20189382 | pubmed:articleTitle | Inhibition of eEF2-K by thieno[2,3-b]pyridine analogues. | lld:pubmed |
| pubmed-article:20189382 | pubmed:affiliation | Department of Medicinal Chemistry, Myriad Pharmaceuticals, 305 Chipeta Way, Salt Lake City, UT 84108, United States. jeffrey.lockman@myriadpharma.com | lld:pubmed |
| pubmed-article:20189382 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:20189382 | lld:chembl |
